Clinical Trials Directory

Trials / Conditions / Glabellar Frown Lines

Glabellar Frown Lines

58 registered clinical trials studyying Glabellar Frown Lines.

StatusTrialSponsorPhase
WithdrawnEfficacy of Zinc Supplementation on Botox Treated Forehead Rhytids
NCT05894109
University of New MexicoN/A
CompletedA Phase 3 Clinical Study to Evaluate the Efficacy and Safety of Botulinum Toxin Type A for Injection (CU-20101
NCT06585696
Cutia Therapeutics（Wuxi）Co.,LtdPhase 3
CompletedA Non-inferiority Clinical Trial to Compare Efficacy and Safety of Abobotulinumtoxin A (Espad Pharmed) Versus
NCT06946160
Espad PharmedPhase 3
CompletedPhase 2a Study of DaxibotulinumtoxinA-lanm for Injection in Dynamic Forehead Lines and Glabellar Lines
NCT06411002
Revance Therapeutics, Inc.Phase 2
CompletedThe Efficacy and Safety of Protoxin in Subjects With Moderate to Severe Glabellar Lines
NCT06124794
Protox Inc.Phase 3
Active Not RecruitingNon Interventional Safety Study of NUCEIVA for the Treatment of Moderate-to-Severe Glabellar Lines
NCT05481931
Evolus, Inc.—
Active Not RecruitingDepth of Botulinum Neurotoxin Injection for Treatment of Glabellar Lines
NCT05766683
Henry Ford Health SystemPhase 1
CompletedThe Efficacy and Safety Study of Protoxin Versus Botox® in Subjects With Moderate to Severe Glabellar Lines
NCT05364580
Protox Inc.Phase 3
CompletedAssess Aesthetic Improvement With QM1114-DP in Subjects With Moderate to Severe Lateral Canthal Lines and Glab
NCT05148000
Galderma R&DPhase 3
UnknownStudy to Compare the Efficacy and Safety of ATGC-110 (Botulinum Toxin) With Xeomin® for the Treatment of Moder
NCT05623410
ATGC Co., Ltd.Phase 3
CompletedAI-09 In Subjects With Glabellar Lines, GL-101
NCT05565950
Eirion Therapeutics Inc.Phase 1 / Phase 2
CompletedAssess Aesthetic Improvement and Onset of QM1114-DP in Subjects With Moderate to Severe Glabellar Lines
NCT05146999
Galderma R&DPhase 3
UnknownXeomin Treatment of Glabellar Lines Using OLD Versus COLD
NCT05305768
Clinical Testing of Beverly HillsEARLY_Phase 1
CompletedStudy to Demonstrate Safety and Duration of Effect of 40 Units of PrabotulinumtoxinA-xvfs to Treat Glabellar L
NCT05320393
Evolus, Inc.Phase 2
CompletedLong-term Extension Study to Evaluate MBA-P01 in Subjects With Moderate to Severe Glabellar Lines
NCT05321979
Medytox KoreaPhase 3
CompletedStudy Comparing Treatment With Alluzience vs Reconstituted Toxin
NCT05277337
Galderma R&DPhase 4
CompletedA Phase II Study to Evaluate the Efficacy and Safety of MBA-P01 in Subjects With Moderate to Severe Glabellar
NCT05217355
Medytox KoreaPhase 2
CompletedJeuveau Treatment of Glabellar Lines Using OLD Versus COLD
NCT05129319
Clinical Testing of Beverly HillsEARLY_Phase 1
UnknownDuration of Botox Using OLD Versus COLD for Treatment of Glabellar Lines
NCT05083286
Clinical Testing of Beverly HillsEARLY_Phase 1
CompletedStudy to Evaluate the Efficacy and Safety of MBA-P01 in Subjects With Glabellar Lines
NCT05059587
Medytox KoreaPhase 3
CompletedSplit-face Study: Cosmetic Botulinum Toxin Type A Injection Under Electromyography-guidance Versus Conventiona
NCT05517538
Mohamed Hayder Oleish SalihN/A
UnknownSplit-Face Study Comparing Botox and Jeuveau in Treating Glabellar Lines
NCT04715048
University of Southern CaliforniaEARLY_Phase 1
CompletedThe Safety and Efficacy Study of PROTOXIN in Subjects With Moderate to Severe Glabellar Lines
NCT04996810
Protox Inc.Phase 1 / Phase 2
CompletedEfficacy and Safety of Botulinum Toxin at Moderate to Severe Glabellar Lines
NCT04830345
EuBiologics Co.,LtdPhase 3
CompletedTreatment of Moderate to Severe Glabellar Lines
NCT04249583
Galderma R&DPhase 3
CompletedA Comparative Study of Botulinum Neurotoxin Type A in Treatment of Moderate to Severe Glabellar Frown Lines
NCT04281095
ATGC Co., Ltd.Phase 1 / Phase 2
UnknownLong-term Open-label Treatment of Moderate to Severe Glabellar Lines With CORETOX®
NCT04281745
Medy-ToxPhase 4
CompletedEfficacy and Safety of a New Dilution and Injection Volume of AbobotulinumtoxinA for the Treatment of Glabella
NCT03960957
Galderma R&DPhase 3
CompletedClinical Trial to Evaluate the Efficacy and Safety of MBA-P01 in Treatment of Glabellar Lines
NCT04143815
Medy-ToxPhase 2
CompletedBotulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study III (BLESSIII)
NCT03985982
Croma-Pharma GmbHPhase 3
CompletedThe Efficacy and Safety of CUNOX® in Patients With Moderate to Severe Glabellar Lines
NCT03837561
Medy-ToxPhase 3
CompletedSafety and Efficacy of AbobotulinumtoxinA for the Treatment of Glabellar Lines
NCT03736928
Galderma R&DPhase 2
CompletedSubject Satisfaction With AbobutulinumtoxinA Treatment
NCT03687736
Galderma R&DPhase 4
UnknownThe Safety and Efficacy Study of Hutox Versus Botox® in Subject With Moderate to Severe Glabellar Lines
NCT03440671
Huons Co., Ltd.Phase 3
CompletedLong-term Safety and Efficacy of MEDITOXIN® in Treatment Glabellar Lines
NCT03289169
Medy-ToxPhase 4
CompletedSafety of Single and Repeat Treatments of DaxibotulinumtoxinA for Injection for Treatment of Moderate to Sever
NCT03004248
Revance Therapeutics, Inc.Phase 3
CompletedEfficacy and Safety of DaxibotulinumtoxinA for Injection to Treat Moderate to Severe Glabellar Lines
NCT03014622
Revance Therapeutics, Inc.Phase 3
CompletedEfficacy and Safety of DaxibotulinumtoxinA for Injection to Treat Moderate to Severe Glabellar Lines
NCT03014635
Revance Therapeutics, Inc.Phase 3
CompletedBotulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study II
NCT02677805
Croma-Pharma GmbHPhase 3
CompletedBotulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study I
NCT02677298
Croma-Pharma GmbHPhase 3
CompletedSafety Study of DWP-450 (Botulinum Toxin, Type a) to Treat Glabellar Lines - EV-006
NCT02428608
Evolus, Inc.Phase 2
CompletedA Phase III Study to Demonstrate the Safety and Efficacy of DWP-450 to Treat Glabellar Lines - EV-002
NCT02334436
Evolus, Inc.Phase 3
CompletedA Phase III Study to Demonstrate the Safety and Efficacy of DWP-450 to Treat Glabellar Lines - EV001
NCT02334423
Evolus, Inc.Phase 3
CompletedEfficacy and Safety of Botulinum Toxin Type A for Injection to Treat Glabellar Lines
NCT02303002
Revance Therapeutics, Inc.Phase 2
CompletedSafety and Efficacy Study of Botulinum Toxin for the Treatment of Glabellar Frown Lines
NCT02236312
Galderma R&DPhase 2
CompletedSafety Study of DWP-450 (Botulinum Purified Neurotoxin, Type A) Injection to Treat Glabellar Lines
NCT02184988
Evolus, Inc.Phase 2
CompletedA Safety and Efficacy Study of Different Injections Volumes of Botulinum Toxin Type A, Azzalure, in the Glabel
NCT02108158
Galderma R&DPhase 4
CompletedThe Treatment of Glabellar Frown Lines
NCT02096081
Merz North America, Inc.Phase 4
CompletedEfficacy and Safety Study of MT10107 in the Treatment of Glabella Line
NCT03908008
Medy-ToxPhase 3
CompletedA Prospective Study Evaluating the Treatment of Forehead and/or Glabellar Lines With the Cryo-Touch IV Device
NCT01801826
Pacira Pharmaceuticals, Inc—
CompletedStudy Evaluating the Treatment of Forehead and/or Glabellar Lines With the CRYO-TOUCH III Device
NCT01808742
Pacira Pharmaceuticals, Inc—
CompletedSafety and Efficacy Study of Botulinum Toxin Type A to Treat Glabellar Lines
NCT01485601
Medy-ToxPhase 2
CompletedPatient Satisfaction Study of BOTOX® Cosmetic in the Treatment of Moderate to Severe Frown Lines
NCT01391312
AllerganPhase 4
CompletedSafety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Forehead and Frown Lines
NCT01391299
AllerganN/A
CompletedSafety and Efficacy Study of Dysport RU and Glabellar Lines
NCT01333397
IpsenPhase 2
CompletedNT 201 (Xeomin®/Bocouture®) in Comparison With Clostridium Botulinum Toxin Type A in the Treatment of Glabella
NCT00777803
Merz Pharmaceuticals GmbHPhase 3
CompletedFinding of Optimal Dose for NT 201 in the Treatment of Glabellar Frown Lines
NCT00430586
Merz Pharmaceuticals GmbHPhase 2
CompletedIncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Glabellar Frown Lines
NCT00430963
Merz Pharmaceuticals GmbHPhase 3